Helix Biopharma Corp.
HBPCF
$0.59
$0.135129.70%
OTC PK
01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 312.40K | 199.90K | 1.75M | 249.10K | 162.20K |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 909.20K | 1.17M | 3.84M | 1.34M | 668.10K |
Operating Income | -909.20K | -1.17M | -3.84M | -1.34M | -668.10K |
Income Before Tax | -967.60K | -978.50K | -3.85M | -1.35M | -668.10K |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -967.60K | -978.50K | -3.85M | -1.35M | -668.10K |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -967.60K | -978.50K | -3.85M | -1.35M | -668.10K |
EBIT | -909.20K | -1.17M | -3.84M | -1.34M | -668.10K |
EBITDA | -907.80K | -1.16M | -3.84M | -1.34M | -665.90K |
EPS Basic | -0.02 | -0.02 | -0.07 | -0.03 | -0.02 |
Normalized Basic EPS | -0.01 | -0.01 | -0.05 | -0.02 | -0.01 |
EPS Diluted | -0.04 | -0.02 | -0.07 | -0.03 | -0.02 |
Normalized Diluted EPS | -0.01 | -0.01 | -0.05 | -0.02 | -0.01 |
Average Basic Shares Outstanding | 50.07M | 49.02M | 52.14M | 42.63M | 41.98M |
Average Diluted Shares Outstanding | 50.07M | 49.02M | 52.14M | 42.63M | 41.98M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |